Med Updates #2
Med Updates #2
A new study by a Prescient Medicine confirms the promise of personalised medicine to predict opioid addiction risk. The study, Multi-variant Genetic Panel for Genetic Risk of Opioid Addiction, was recently published in Annals of Clinical & Laboratory Science features a test called LifeKit Predict was developed based on genetic factors playing a significant role in prescription opioid addiction. The study first described genetic variations between addicted and non-addicted populations and used this in order to establish a predictive algorithm to determine opioid addiction risk. It was found to produce an addiction risk score based on 16 single nucleotide polymorphisms (SNPs) in the brain reward pathways. The criteria for the 37 patients were prescription opioid or heroin addiction and 30 age and gender matched non-addicted patients.
To ensure understanding of the roles of genes and the brain reward pathways, they consulted with AutoGenomics, Inc who researched the literature to identify candidate genes to be markers. The data has confirmed many previously published studies indicating a strong genetic component to opioid addiction. Following the first study, 138 patient samples were evaluated to assess the efficacy of the panel. This show a 97% certainty that an individual has a low likelihood of becoming addicted to opioids and an 88% likelihood of predicting that an individual has an increased risk for opioid addiction. This novel study allows physicians to prevent addictions from beginning by choosing non-opioid therapies for at-risk patients. As the opioid crisis has been deemed the deadliest drug overdose crisis in U.S. history, the importance of this is invaluable. Over 59,000 opioid related drug overdoses were reported in 2016. The economic impact is still being predicted as opioid-related hospitalisations cost around 20 billion dollars annually. Then calculate in social services, public safety, and criminal justice fees measuring in at 83 billion dollars. Estimates for the next 10 years predict 650,000 deaths from opioid use.
The poster presentation of this study was selected by as the recipient of the 2017 Industry Division Poster Award at the American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo.